Bod Australia (ASX:BDA) revenue up 94.5% on PCP in 1H FY2020 report.

"The first half of FY2020 has been transformational for Bod and we have achieved a great deal. Not only have we considerably increased revenue on the previous corresponding period, but also witnessed the first material sales from Bod’s medicinal cannabis products and CBD products in collaboration with H&H Group. Early signs are encouraging and we are confident that we will continue to aggressively build top line growth while at the same time maintaining a strong focus on cost control. The Company’s strategic agreement with H&H Group means Bod is uniquely and very well positioned to rapidly expand through the commercialisation of CBD and hemp products. Bod is set to launch a number of products under new and existing brands in the second half of FY2020, which will enhance revenue streams. MediCabilis™ prescription volumes continue to grow at a steady clip and growth will be helped by progressing an expansion into the United Kingdom in the coming weeks and the well-documented launch of two new CBD products. The second half has commenced well for Bod and the Company is in excellent shape."